Proprietary Dermal Delivery Platform.
Live in The US Market & Ready to Scale.
WHY ARE WE RAISING CAPITAL?
The bridge between early commercial validation and institutional-scale growth.
EncapSolutions is raising to accelerate the commercial rollout of the SkinSync® transdermal delivery platform — the technology that makes our patches work differently from anything else on the market.
The capital funds three specific outcomes: GMP certification of our Australian manufacturing facility, scaling our U.S. direct-to-consumer channel, and formalising the pharmaceutical co-development partnerships that represent the next phase of the platform's value.
This is not a startup searching for a business model. The platform works, the products are live, and the capital we are raising now is the bridge between early commercial validation and institutional-scale growth.
WHY ENCAPSOLUTIONS?
A proprietary platform, validated and protected.
SkinSync® is a proprietary nanofibre transdermal delivery platform developed in Sydney. Our electrospinning process encapsulates active compounds within an ultrafine polymer matrix, engineered to dissolve at the skin surface at a controlled rate. Patent applications covering the core platform technology have been filed across key international jurisdictions.
Up to 30x
GREATER PAYLOAD EFFICIENCY
$7Bn+
GLOBAL PATCH MARKET
2
MARKET: CONSUMER & PHARMA
WHY NOW?
Three converging milestones.
GMP Certification
Our GMP-capable cleanroom facility in Sydney is operational. Capital raised now completes certification unlocking pharmaceutical-grade manufacturing.
U.S. Commercial Channel Live
Shopify is active. Amazon Brand Store launches July 2026. Paid acquisition commenced June 2026.
Co-Developments
Discussions are underway. The window to enter this raise at the current valuation closes when those discussions formalise.
WHY PATCHES?
A $7B+ market waiting for a better delivery system
The transdermal patch market is worth over USD $7 billion globally and growing, driven by demand for drug delivery formats that bypass the digestive system, reduce dosing frequency, and improve patient compliance. Conventional patch technology wastes the majority of its active load — the market isn't waiting for a new product, it's waiting for a better delivery system.
Want to know more about the deal
Fill a brief questionnaire to get access to the more information about the investment deal